Neurogene, Inc. (NGNE)
28.31
-2.94
(-9.41%)
USD |
NASDAQ |
Sep 25, 16:00
28.32
+0.01
(+0.04%)
After-Hours: 19:59
Neurogene Enterprise Value : 231.11M for Sept. 25, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Enterprise Value Data
| Date | Value |
|---|---|
| September 25, 2026 | 231.11M |
| September 24, 2026 | 277.66M |
| September 23, 2026 | 272.59M |
| September 22, 2026 | 314.86M |
| September 21, 2026 | 298.55M |
| September 18, 2026 | 290.95M |
| September 17, 2026 | 296.02M |
| September 16, 2026 | 331.80M |
| September 15, 2026 | 316.28M |
| September 14, 2026 | 340.34M |
| September 11, 2026 | 344.62M |
| September 10, 2026 | 354.75M |
| September 09, 2026 | 382.61M |
| September 08, 2026 | 386.57M |
| September 04, 2026 | 394.01M |
| September 03, 2026 | 378.34M |
| September 02, 2026 | 390.21M |
| September 01, 2026 | 382.45M |
| August 31, 2026 | 356.65M |
| August 28, 2026 | 362.03M |
| August 27, 2026 | 382.30M |
| August 26, 2026 | 391.00M |
| August 25, 2026 | 429.47M |
| August 24, 2026 | 410.47M |
| August 21, 2026 | 394.49M |
| Date | Value |
|---|---|
| August 20, 2026 | 384.35M |
| August 19, 2026 | 407.15M |
| August 18, 2026 | 347.63M |
| August 17, 2026 | 363.62M |
| August 14, 2026 | 355.07M |
| August 13, 2026 | 346.99M |
| August 12, 2026 | 368.36M |
| August 11, 2026 | 349.68M |
| August 10, 2026 | 361.56M |
| August 07, 2026 | 347.94M |
| August 06, 2026 | 346.52M |
| August 05, 2026 | 352.53M |
| August 04, 2026 | 327.68M |
| August 03, 2026 | 303.30M |
| July 31, 2026 | 303.62M |
| July 30, 2026 | 314.86M |
| July 29, 2026 | 315.81M |
| July 28, 2026 | 308.84M |
| July 27, 2026 | 331.00M |
| July 24, 2026 | 335.44M |
| July 23, 2026 | 346.04M |
| July 22, 2026 | 354.59M |
| July 21, 2026 | 363.62M |
| July 20, 2026 | 374.06M |
| July 17, 2026 | 373.59M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| ACADIA Pharmaceuticals, Inc. | 2.677B |
| Alnylam Pharmaceuticals, Inc. | 33.91B |
| Anika Therapeutics, Inc. | 259.45M |
| Savara, Inc. | 884.37M |
| Vericel Corp. | 1.964B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -34.49M |
| Total Expenses (Quarterly) | 34.49M |
| EPS Diluted (Quarterly) | -1.529 |
| Earnings Yield | -19.44% |
| Normalized Earnings Yield | -19.44 |